Evan Delancey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Evan Delancey has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Alexei G. Basnakian
University of Arkansas for Medical Sciences
1 shared publication - David F. Gilmore
Department of Biological Sciences, The College of Sciences and Mathematics, Arkansas State University, Jonesboro, AR 72401, USA
1 shared publication - Devin Allison
University of Missouri School of Medicine, Columbia. Drs. Parker and Martin are from the Department of Dermatology
1 shared publication - Hansa Raj Kc
Department of Chemistry and Physics, The College of Sciences and Mathematics, Arkansas State University, Jonesboro, AR 72401, USA
1 shared publication - Mohammad Abrar Alam
Arkansas State University
1 shared publication - Todd Fite
Department of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, 4301 W. Markham St., Little Rock, AR 72205, USA
1 shared publication
Latest Publications
- Open Access
- 28 September 2020
- Published by MDPI AG in Antibiotics
- Vol. 9 (10) , 650
Synthesis of 4,4′-(4-Formyl-1H-pyrazole-1,3-diyl)dibenzoic Acid Derivatives as Narrow Spectrum Antibiotics for the Potential Treatment of Acinetobacter Baumannii Infections
Acinetobacter baumannii has emerged as one of the most lethal drug-resistant bacteria in recent years. We report the synthesis and antimicrobial studies of 25 new pyrazole-derived hydrazones. Some of these molecules are potent and specific inhibitors of A. baumannii strains with a minimum inhibitory concentration (MIC) value as low as 0.78 µg/mL. These compounds are non-toxic to mammalian cell lines in in vitro studies. Furthermore, one of the potent molecules has been studied for possible in vivo toxicity in the mouse model and found to be non-toxic based on the effect on 14 physiological blood markers of organ injury.
- 28 September 2020
- Published by MDPI AG in Antibiotics
- Vol. 9 (10) , 650
Open AccessSynthesis of 4,4′-(4-Formyl-1H-pyrazole-1,3-diyl)dibenzoic Acid Derivatives as Narrow Spectrum Antibiotics for the Potential Treatment of Acinetobacter Baumannii Infections
Acinetobacter baumannii has emerged as one of the most lethal drug-resistant bacteria in recent years. We report the synthesis and antimicrobial studies of 25 new pyrazole-derived hydrazones. Some of these molecules are potent and specific inhibitors of A. baumannii strains with a minimum inhibitory concentration (MIC) value as low as 0.78 µg/mL. These compounds are non-toxic to mammalian cell lines in in vitro studies. Furthermore, one of the potent molecules has been studied for possible in vivo toxicity in the mouse model and found to be non-toxic based on the effect on 14 physiological blood markers of organ injury.